The safety results appear to be ok, and TAF will almost certainly be advanced to phase-3.
This compound is quite important to GILD’s HIV franchise insofar as the US CoM patents on Viread expire in 2017 and the other Orange Book patents on Viread and Emtriva strike me as weak.
*Tenofovir alafenamide fumarate, which is a prodrug of the same active ingredient (tenofovir) as Viread.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.